Option chain shows key data for Molecular Templates's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Molecular Templates.

Molecular Templates (OTC:MTEM) Stock, Option Chain

Molecular Templates

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.

News

MTEM

Molecular Templates shares are trading lower by 54% during Friday&#39;s session. The company announced it received a Nasdaq delisting notice.

Why Molecular Templates (MTEM) Stock Is Down 60%

FedEx.Shutterstock

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

NVNI

OCEA

PRFX

QUBT

ZCAR

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

DocuSign.How-it-Works_2020_thumb_Update

Pre-Market Outlook

Movers

Trading Ideas

ASAN

CAMP

DOCU

FOXX

GXAI

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

ORIS

PGHL

RBRK

SATL

SWBI

TARA

VRPX

ZBAO

ZSPC

Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

MOLECULAR TEMPLATES INC by Molecular Templates, Inc.

Molecular Templates Inc

Jefferies analyst Julien Dumoulin-Smith downgrades Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Buy to Hold and lowers the price target from $22 to $15.

Downgrades

Price Target

Analyst Ratings

FLNC

Jefferies Downgrades Fluence Energy to Hold, Lowers Price Target to $15

B of A Securities analyst Jessica Reif Ehrlich maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and raises the price target from $1000 to $1175.

NFLX

B of A Securities Maintains Buy on Netflix, Raises Price Target to $1175

BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.70 by 30 percent. The company reported quarterly sales of $264.464 million which beat the analyst consensus estimate of $261.080 million by 1.30 percent. This is a 12.87 percent increase over sales of $234.302 million the same period last year.

Earnings

Earnings Beats

BankUnited Q4 2024 GAAP EPS $0.91 Beats $0.70 Estimate, Sales $264.464M Beat $261.080M Estimate

Needham analyst Quinn Bolton upgrades Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) from Hold to Buy and announces $16 price target.

Upgrades

CRNC

Needham Upgrades Cerence to Buy, Announces $16 Price Target

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)</h3>
<ul>
<li>On Jan. 17, HC Wainwright &amp; Co. analyst Joseph Pantginis reiterated Viking Therapeutics with a Buy and maintained a $102 price target.. The company' stock fell around 22% over the past month and has a <a href="https://www.benzinga.com/quote/VKTX">52-week low of $20.83</a>.</li>
<li>RSI Value: 28.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VKTX Price Action: Shares of Viking Therapeutics gained 0.7% to close at $32.87 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">latest VKTX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png" alt="" class="wp-image-744179" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-768x707.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Radnet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Jan. 15, Jefferies analyst Brian Tanquilut maintained RadNet with a Buy rating and lowered the price target from $100 to $80. The company's stock fell around 11% over the past five days and <a href="https://www.benzinga.com/quote/RDNT">has a 52-week low</a> of $35.16.</li>
<li>RSI Value: 25.2</li>
<li>RDNT Price Action: Shares of Radnet gained 0.6% to close at $60.19 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">trend in RDNT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png" alt="" class="wp-image-744183" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-768x704.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>)</h3>
<ul>
<li>On Jan. 13, Vera Therapeutics secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera's position in B cell modulation. The company's stock fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/VERA">low of $15.46.</a></li>
<li>RSI Value: 27.2</li>
<li>VERA Price Action: Shares of Vera Therapeutics gained 1% to close at $33.70 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">VERA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png" alt="" class="wp-image-744188" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-768x719.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Long Ideas

Markets

RDNT

VERA

VKTX

Top 3 Health Care Stocks That Could Blast Off This Quarter

Canaccord Genuity analyst Austin Moeller maintains Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) with a Buy and lowers the price target from $20 to $18.

CBUS

Canaccord Genuity Maintains Buy on Cibus, Lowers Price Target to $18

International Game Technology Announced That Its Subsidiary Signed A Seven-year Contract With The Thuringian State Lottery In Germany To Deploy Its Retail Central System Technology, Aurora, And Related Software Upgrades

Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.69 by 1.45 percent. This is a 5.41 percent decrease over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $5.61 billion which missed the analyst consensus estimate of $5.63 billion by 0.27 percent. This is a 2.25 percent decrease over sales of $5.74 billion the same period last year.

Earnings Misses

Halliburton Q4 2024 GAAP EPS $0.70 Beats $0.69 Estimate, Sales $5.61B Miss $5.63B Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and lowers the price target from $14 to $11.

RVPH

HC Wainwright & Co. Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $11

The removal of the $7500 federal tax credit on the purchase of electric vehicles will effectively raise the price of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) vehicles in the U.S. as compared to its peers and pose a huge negative catalyst for the company, The Future Fund Managing Partner Gary Black said on Tuesday. 
What Happened: While about nine Tesla vehicle models currently qualify for the tax credit, only 12 vehicles from rival brands qualify. 
Black, himself a Tesla bull, slammed bullish opinions of the removal of tax credit harming competitors over Tesla and said, &#8220;Mathematically that makes no sense, with TSLA US roughly 30-35% of TSLA global volume, and General Motors, Ford, Stellantis US EVs accounting for 4-5% of their respective global volumes.&#8221;
The removal of the tax credit will also not likely move rivals out of the EV segment, Black said. &#8220;That is the same argument I heard when TSLA cut EV prices in 2022-2023. In reality, everyone matched the TSLA-led price cuts, no one gave up, and $TSLA stock got hurt the worst in the ensuing price war,&#8221; he noted. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">2/ I keep hearing the same dumb argument that the loss of upfront EV credits hurts competition more than TSLA. Mathematically that makes no sense, with TSLA US roughly 30-35% of TSLA global volume, and <a href="https://twitter.com/search?q=%24GM&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GM</a> <a href="https://twitter.com/search?q=%24F&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$F</a> <a href="https://twitter.com/search?q=%24STLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$STLA</a> <a href="https://twitter.com/search?q=%24VOW&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$VOW</a> US EVs accounting for 4-5% of their respective global…
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1881859645515460836?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: In November, Reuters reported that&nbsp;Donald Trump‘s transition team plans to kill the $7,500 tax credit available on EV purchases. On Monday, after his inauguration, Trump himself said his administration would consider ending EV tax credits.
Currently, multiple <a href="https://www.benzinga.com/tech/25/01/43090016/here-are-the-evs-which-could-lose-7500-ev-tax-credit-under-trump-administration">Tesla vehicles qualify for a $7500 federal tax credit</a> including the single-motor and dual-motor Cybertruck, all three variants of the Model 3 and Model Y, and the all-wheel drive variant of the Model X.
Rival models that qualify for the credit include the Honda Prologue, the Cadillac Optiq, LT Model of the Chevrolet Silverado EV, among others. 
Tesla CEO Elon Musk has previously dismissed the impact of a drop in EV tax credit for Tesla saying that the impact of the elimination of subsidies&nbsp;<a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably" target="_blank" rel="noreferrer noopener">would only be slight for Tesla</a>&nbsp;but devastating for its competitors. The elimination of EV subsidies would probably help Tesla in the long term, he added.
While some other Tesla bulls also hold similar opinions, some including Black are skeptical. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43120483/ford-mustang-architect-hal-sperlich-dies-at-95-lot-of-people-who-make-great-cars-but-so-few-who-invent-segments-like-hal-did-says-jim-farley">Ford Mustang Architect Hal Sperlich Dies At 95: &#8216;Lot Of People Who Make Great Cars But So Few Who Invent Segments Like Hal Did,&#8217; Says Jim Farley</a></li>
</ul>

Equities

TSLA

Trump's Plan To Revoke $7,500 EV Tax Credit Is A 'Huge' Negative For Tesla, Says Gary Black, Downplays Impact On Rivals

Needham analyst John Todaro maintains Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) with a Buy and raises the price target from $11 to $16.

RIOT

Needham Maintains Buy on Riot Platforms, Raises Price Target to $16

On Tuesday, January 21st, U.S. markets closed mixed, with the S&amp;P 500 and Dow reaching month-highs as investors welcomed a restrained approach to tariffs in President Trump&#8217;s initial actions. While concerns about trade policy persist, markets were buoyed by hopes for a more strategic, negotiable approach to tariffs.
Most sectors on the S&amp;P 500 closed higher on Tuesday, with notable gains in industrials, real estate, and health care, reflecting broad market strength. However, energy stocks diverged from the overall positive trend, ending the session lower amid sector-specific pressures.
The Dow Jones Industrial Average was up 1.24% and closed at 44,025.81, the S&amp;P 500 closed higher by 0.88% at 6,049.24, and the Nasdaq Composite rose 0.64% to finish at 19,756.78.
Aisa Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed higher by 1.58% at 39,615.50, led by gains in the Precision Instruments, Manufacturing and Textile sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.33%, ending the session at 8,429.80, led by gains in the IT, Gold, and Industrials sectors.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.58% at 23,159.30, while the Nifty 500 declined 0.15%, closing at 21,400.80.</li>
<li>China&#8217;s Shanghai Composite declined 0.89% and closed at 3,213.62, and the Shenzhen CSI 300 slid 0.93%, finishing the day at 3,797.02.</li>
<li>Hong Kong Hang Seng closed the session lower by 1.63% at 19,778.77.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was up 0.83%.</li>
<li>Germany&#8217;s DAX rose 1.13%.</li>
<li>France&#8217;s CAC rose 0.77%.</li>
<li>U.K.&#8217;s FTSE index 100 traded higher by 0.24%.</li>
<li>European stocks rose modestly Wednesday amid cautious sentiment on trade threats from Trump&#8217;s administration. The focus remained on Davos, ECB rate cuts, EasyJet&#8217;s recovery, AI investments, and oil price drops due to U.S. output plans.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.58% at $76.27/bbl, and Brent was up 0.49% at $79.70/bbl.</li>
<li>Oil prices fell further Wednesday as markets reacted to Trump&#8217;s energy emergency declaration, plans to maximize U.S. production, and potential tariffs on Canada and Mexico amid mixed global demand signals.</li>
<li>Natural Gas gained 0.53% to $3.776.</li>
<li>Gold was trading higher by 0.49% at $2,772.71, Silver was up 0.42% to $31.628, and Copper fell 0.24% to $4.3305.</li>
<li>Gold prices rose to an 11-week high amid safe-haven demand driven by tariff uncertainties under Trump&#8217;s administration, while copper prices dropped on weaker demand prospects and stronger dollar concerns.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were up 0.13%, S&amp;P 500 futures rose 0.40% and Nasdaq 100 futures gained 0.78%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index declined 0.14% to 107.80, USD/JPY gained 0.14% to 155.71, and USD/AUD declined 0.26% to 1.6897.</li>
<li>The dollar hovered near two-week lows amid uncertainty over Trump&#8217;s tariff plans, with mixed currency movements reflecting cautious sentiment.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mixed, Europe Up As Trump's Tariff Plans Sparks Market Caution; Gold Hits 11-Week High - Global Markets Today While US Slept

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and maintains $26 price target.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Maintains $26 Price Target

JFBR

Jeffs' Brands announced that it has issued a non- recourse convertible promissory note in the principal amount of $2,850,000 to an institutional investor

WIIM

GE Vernova shares are trading lower after the company reported worse-than-expected Q4 EPS and revenue.

Telsey Advisory Group analyst Dana Telsey maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Market Perform and maintains $21 price target.

Telsey Advisory Group Maintains Market Perform on VF, Maintains $21 Price Target

Needham analyst Gil Blum initiates coverage on Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy rating and announces Price Target of $9.

Initiation

ABSI

Needham Initiates Coverage On Absci with Buy Rating, Announces Price Target of $9

Guidance

Textron Sees FY25 Adj. EPS $6.00-$6.20 vs $6.42 Est.

Potter will also join the Company's Board of Directors. Potter will succeed Eric J. Lindberg, Jr., who has served as Interim President and Chief Executive Officer since October 2024.&nbsp;

Management

Grocery Outlet Holding Appoints Jason Potter As President And CEO, Effective February 3, 2025

Textron Q4 2024 Adj. EPS $1.34, Inline, Sales $3.613B Miss $3.810B Estimate

Press Releases

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Molecular Templates, Inc. Provides Interim Update

Financing

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

Molecular Templates, Inc. Reports First Quarter  2024 Financial Results and Corporate Update

Health Care

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

Barclays

B of A Securities

Comments

Molecular Templates

Molecular Templates (MTEM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga